Tradestie Institutional Equity Comparison Engine
XNCR vs XENE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XNCR Overall Edge
XNCR Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xencor, Inc. (XNCR) driven by superior Valuation, Momentum & Technical, Options & Structure while XENE counters with relative strength in Growth & Margin. Fundamentally, XNCR trades at 68.0x Forward P/E with -72.7% operating margin (+454.9% YoY revenue) versus XENE at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, XNCR sits in BREAKOUT (10th %ile IV; Dealer Gamma Walls on Pro) against XENE sits in BREAKDOWN (14th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
XNCR
XNCR 68.0x vs XENE N/M Fwd P/E
Growth & Margin Winner
XENE
Op Margin -72.7% vs 0.0% ยท YoY +454.9% vs -100.0%
Momentum & Technical Winner
XNCR
1Y +154.5% vs -1.8% ยท 52W Pos 84% vs 15%
Options & Structure Winner
XNCR
BREAKOUT (10th %ile IV) vs BREAKDOWN (14th %ile IV)
XNCR
NASDAQ
Xencor, Inc.
Pharmaceutical Preparations
$35.61
-3.99% 1D
Market Cap
$2.9B
1M Return
+55.84%
1Y Return
+154.54%
Forward P/E
68.0x
Unified AI Score
29.6 / 100
SELL
Tech 50.0
Fund 32.0
Flow 66.0
Mom 40.0
XENE
NASDAQ
Xenon Pharmaceuticals Inc
Pharmaceutical Preparations
$39.30
-2.9% 1D
Market Cap
$4.0B
1M Return
+17.36%
1Y Return
-1.84%
Forward P/E
N/M
Unified AI Score
33.3 / 100
SELL
Tech 15.0
Fund 44.0
Flow 68.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XNCR +154.54%
XENE -1.84%
Spread: +156.38 pp (XNCR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XNCR Revenue | XENE Revenue | XNCR Op. Margin | XENE Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $40M | N/A | -195.5% | N/A | XNCR |
| FY2019 | $160M | $10M | 8.8% | -627.0% | XNCR |
| FY2020 | $120M | $30M | -62.6% | -97.3% | XNCR |
| FY2021 | $280M | $20M | 15.9% | -428.4% | XNCR |
| FY2022 | $160M | $10M | -50.1% | -1368.9% | XNCR |
| FY2023 | $170M | N/A | -75.8% | N/A | XNCR |
| FY2024 | $110M | N/A | -161.5% | N/A | XNCR |
| FY2025 | $130M | $10M | -141.4% | -4974.3% | XNCR |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XNCR | XENE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.9B | $4.0B | Larger Scale | XENE |
| Trailing P/E Ratio Valuation | 68.0x | N/M | Lower Multiple | XNCR |
| Forward P/E Ratio Valuation | 68.0x | N/M | Lower Multiple | XNCR |
| Revenue Growth (YoY) Growth | +454.9% | -100.0% | Higher Growth | XNCR |
| Operating Margin (TTM) Profitability | -72.7% | 0.0% | Higher Margin | XENE |
| Net Profit Margin Profitability | -58.8% | 0.0% | Higher Margin | XENE |
| Return on Equity (ROE) Capital Efficiency | -19.9% | -50.3% | Higher ROE | XNCR |
| 52-Week Range Position Momentum | 84% ($10โ$41) | 15% ($33โ$73) | Stronger Trend | XNCR |
| Beta / 30D Volatility Risk Regime | 1.21ฮฒ ยท 87% Vol | 0.70ฮฒ ยท 36% Vol | Lower Realized Risk | XENE |
| Unified Institutional Score Composite Signal | 29.6 / 100 (SELL) | 33.3 / 100 (SELL) | Higher Composite | XENE |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XNCR vs XENE Buy Guide
XNCR
BREAKOUT
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
10th %ile
IV Regime
Compressed (<25th %ile)
XENE
BREAKDOWN
175d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
14th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XNCR nor XENE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.